Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 3
1978 1
1979 1
1980 4
1981 1
1982 1
1983 1
1984 1
1985 1
1987 3
1989 4
1991 5
1992 1
1993 1
1994 3
1995 1
1997 3
1998 4
1999 2
2000 4
2001 4
2002 5
2003 9
2004 11
2005 10
2006 13
2007 12
2008 16
2009 17
2010 11
2011 19
2012 27
2013 36
2014 31
2015 58
2016 49
2017 92
2018 82
2019 73
2020 99
2021 93
2022 94
2023 85
2024 88

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

936 results

Results by year

Filters applied: . Clear all
Page 1
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. Among authors: ferrante m. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. D'Haens G, et al. Among authors: ferrante m. Lancet. 2022 May 28;399(10340):2015-2030. doi: 10.1016/S0140-6736(22)00467-6. Lancet. 2022. PMID: 35644154 Clinical Trial.
European Crohn's and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation.
Torres J, Chaparro M, Julsgaard M, Katsanos K, Zelinkova Z, Agrawal M, Ardizzone S, Campmans-Kuijpers M, Dragoni G, Ferrante M, Fiorino G, Flanagan E, Gomes CF, Hart A, Hedin CR, Juillerat P, Mulders A, Myrelid P, O'Toole A, Rivière P, Scharl M, Selinger CP, Sonnenberg E, Toruner M, Wieringa J, Van der Woude CJ. Torres J, et al. Among authors: ferrante m. J Crohns Colitis. 2023 Jan 27;17(1):1-27. doi: 10.1093/ecco-jcc/jjac115. J Crohns Colitis. 2023. PMID: 36005814 Free article. No abstract available.
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr; INSPIRE and COMMAND Study Group. Louis E, et al. Among authors: ferrante m. JAMA. 2024 Sep 17;332(11):881-897. doi: 10.1001/jama.2024.12414. JAMA. 2024. PMID: 39037800 Clinical Trial.
Vedolizumab for the Treatment of Chronic Pouchitis.
Travis S, Silverberg MS, Danese S, Gionchetti P, Löwenberg M, Jairath V, Feagan BG, Bressler B, Ferrante M, Hart A, Lindner D, Escher A, Jones S, Shen B; EARNEST Study Group. Travis S, et al. Among authors: ferrante m. N Engl J Med. 2023 Mar 30;388(13):1191-1200. doi: 10.1056/NEJMoa2208450. N Engl J Med. 2023. PMID: 36988594 Clinical Trial.
Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening.
Boretto M, Maenhoudt N, Luo X, Hennes A, Boeckx B, Bui B, Heremans R, Perneel L, Kobayashi H, Van Zundert I, Brems H, Cox B, Ferrante M, Uji-I H, Koh KP, D'Hooghe T, Vanhie A, Vergote I, Meuleman C, Tomassetti C, Lambrechts D, Vriens J, Timmerman D, Vankelecom H. Boretto M, et al. Among authors: ferrante m. Nat Cell Biol. 2019 Aug;21(8):1041-1051. doi: 10.1038/s41556-019-0360-z. Epub 2019 Aug 1. Nat Cell Biol. 2019. PMID: 31371824
Authors' Response.
Ferrante MJ, Bellows LL, Johnson SL, Miller J, Slejko GS. Ferrante MJ, et al. J Acad Nutr Diet. 2022 Jan;122(1):30-31. doi: 10.1016/j.jand.2021.10.013. Epub 2021 Oct 29. J Acad Nutr Diet. 2022. PMID: 34756791 No abstract available.
Neuromuscular electrodiagnosis.
Ferrante MA. Ferrante MA. Handb Clin Neurol. 2023;195:251-270. doi: 10.1016/B978-0-323-98818-6.00019-4. Handb Clin Neurol. 2023. PMID: 37562871 Review.
What are the Unmet Needs and Most Relevant Treatment Outcomes According to Patients with Inflammatory Bowel Disease? A Qualitative Patient Preference Study.
Schoefs E, Vermeire S, Ferrante M, Sabino J, Lambrechts T, Avedano L, Haaf I, De Rocchis MS, Broggi A, Sajak-Szczerba M, Saldaña R, Janssens R, Huys I. Schoefs E, et al. Among authors: ferrante m. J Crohns Colitis. 2023 Apr 3;17(3):379-388. doi: 10.1093/ecco-jcc/jjac145. J Crohns Colitis. 2023. PMID: 36165579 Free PMC article. Review.
936 results